



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ :A61K 31/505, C07D 471/00
C07D 401/00, 239/72, 419/00

A1

(11) International Publication Number:

WO 92/13535

(43) International Publication Date:

20 August 1992 (20.08.92)

(21) International Application Number: PCT/US91/00788

(22) International Filing Date: 6 February 1991 (06.02.91)


(71)(72) Applicants and Inventors: DWIVEDI, Chandradhar
[US/US]; 1825 Skyview Lane, Brookings, SD 57006
(US). OMODT, Gary, W. [US/US]; 112 Lincoln Lane
So., Brookings, SD 57006 (US).(74) Agent: KARNY, Geoffrey, M.; Dickstein, Shapiro & Mor-
in, 2101 L Street, N.W., Washington, DC 20037 (US).

(81) Designated States: CA, JP.

Published

With international search report.

(54) Title: ANTICONVULSANT SUBSTITUTED QUINAZOLONES



(II)

(57) Abstract

Disclosed herein are substituted quinazolinones and their N¹-oxide derivatives, methods of synthesizing such compounds, and methods of using them to treat or prevent convulsions in mammals. The substituted quinazolinones are represented by formula (II): wherein X₁ is N, S, O, or CH, X₂ is N or CH, R₁ and R₂ are H, NO₂, or NH₂ except that when one of R₁ and R₂ is NO₂ or NH₂ the other is H, R₃ and R₄ are alkyl with 1-5 C atoms, and R₅, R₆, and R₇ are H or halogen, provided that when X₁ is N, S, or O, X₂ is CH.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FI	Finland	ML	Mali
AU	Australia	FR	France	MN	Mongolia
BB	Barbados	GA	Gabon	MR	Mauritania
BE	Belgium	GB	United Kingdom	MW	Malawi
BF	Burkina Faso	GN	Guinea	NL	Netherlands
BG	Bulgaria	GR	Greece	NO	Norway
BJ	Benin	HU	Hungary	PL	Poland
BR	Brazil	IE	Ireland	RO	Romania
CA	Canada	IT	Italy	RU	Russian Federation
CF	Central African Republic	JP	Japan	SD	Sudan
CG	Congo	KP	Democratic People's Republic of Korea	SE	Sweden
CH	Switzerland	KR	Republic of Korea	SN	Senegal
CI	Côte d'Ivoire	LI	Liechtenstein	SU	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TC	Togo
DE	Germany	MC	Monaco	US	United States of America
DK	Denmark	MG	Madagascar		
ES	Spain				

ANTICONVULSANT SUBSTITUTED QUINAZOLONESFIELD OF THE INVENTION

This invention relates generally to anticonvulsant compounds and their use and specifically to substituted quinazolones that have anticonvulsant activity but limited or no sedative or hypnotic effect.


REFERENCES

Several publications are referenced herein by Arabic numerals within parenthesis. Full citations for these references may be found at the end of the specification immediately preceding the claims. The disclosures of these publications are hereby incorporated herein by reference in their entirety, unless otherwise noted.

BACKGROUND OF THE INVENTION

Gujral et al. (1,2) synthesized methaqualone (2-methyl-3-o-tolyl-4-quinazolone) and reported its sedative and hypnotic effect. In addition, it also possesses anticonvulsant, antispasmodic, local anesthetic, and weak antihistaminic properties (3). Unfortunately, the drug has high abuse potential and has been withdrawn from the market in the United States. It is represented by the following formula:

- 2 -



Numerous derivatives of methaqualone have been prepared. For example, 2-methyl-3-(2-trifluoromethylphenyl)-4-quinazolinone was synthesized by Klosa and Starke. A comparison of this compound with methaqualone showed lower toxicity and better sedative effect (4). Some 4-oxo-3,4-dihydroquinazolines were prepared. These products exhibited various types of physiological activity (5). Anticonvulsant activity of 2-methyl-3-p-bromophenyl-4-quinazolinone has been reported against pentylenetetrazol induced seizures (6). A number of derivatives of 2,3-substituted 4-quinazolones were synthesized. These compounds exhibited antiphlogistic, analgesic, antipyretic, and anticonvulsive effects (7). Bhaduri and Khanna synthesized 2,3-substituted 4-quinazolones and 8-aza quinazolones as potential CNS-depressants (8). Quinazolinone hydrazides were synthesized, and these hydrazides exhibited some anticonvulsant activity (9, 10, 11). However, there is still a need for a safe anticonvulsant compound that has limited or no sedative or hypnotic effect.

In order to decrease the hypnotic property and abuse potential of methaqualone and retain the anticonvulsant activity, we attempted to decrease the lipid solubility of the drug by introducing a hetero nitrogen atom in the

- 3 -

phenyl ring at position 3, at position 8, or at both positions. We also attempted to decrease lipid solubility by introducing a NH_2 group at position 6 or 7 of the quinazolone nucleus. Several other structural analogs of methaqualone were also prepared and evaluated for anticonvulsant activity. We discovered certain substituted quinazolones with anticonvulsant activity but with limited or no sedative or hypnotic effect.

SUMMARY OF THE INVENTION

It is an object of the invention to provide new anticonvulsant compounds that have limited or no sedative or hypnotic effect.

It is a further object of the invention to provide pharmaceutically acceptable salts of the new anticonvulsant compounds.

A still further object of the invention is to provide a composition for treating or preventing convulsions in mammals.

Another object of the invention is to provide methods of treating or preventing convulsions in mammals.


Yet another object of the invention is to provide methods for synthesizing the novel anticonvulsant compounds.

Still another object of the invention is to provide intermediate compounds useful in the synthesis of the anticonvulsant compounds of the invention.

- 4 -

Additional objects and advantages of the invention will be set forth in part in the description that follows, and in part will be obvious on the description, or may be learned by the practice of the invention. The objects and advantages of the invention will be attained by means of the instrumentalities and combinations particularly pointed out in the appended claims.

To achieve the objects and in accordance with the purpose of the invention, as embodied and broadly described herein, the present invention provides compounds represented by the following formula:



II

in which X_1 is N, S, O, or CH, X_2 is N or CH, R_1 and R_2 are H, NO_2 , or NH_2 except that when one of R_1 and R_2 is NO_2 or NH_2 the other is H, R_3 and R_4 are alkyl with 1-5 C atoms, and R_5 , R_6 , and R_7 are H or halogen, provided that when X_1 is N, S, or O, X_2 is CH. The invention also includes pharmaceutically acceptable salts of these compounds.

- 5 -

In a preferred embodiment, X_1 is N. When X_1 is N, preferably R_3 and R_4 are methyl, and R_5 , R_6 , and R_7 are H.

In alternative preferred embodiment, one of R_1 and R_2 is NO_2 or NH_2 . In this case, preferably X_1 is N or CH, R_3 and R_4 are methyl, and R_5 , R_6 , and R_7 are H.

It has been found that the compounds of the invention and the physiologically acceptable acid addition salts have valuable pharmacological properties. In particular, they have anticonvulsant activity with limited or no sedative or hypnotic effect. Thus, the compounds, the acid addition salts, and compositions containing the compounds or salts in a pharmaceutically acceptable carrier are useful for treating or preventing convulsions in mammals in general and humans in particular.

The compounds of the invention are prepared in one of two ways. Where both R_1 and R_2 are H or one of R_1 and R_2 is NO_2 , the appropriate substituted anthranilic acid is reacted with the appropriate anhydride to produce an anthranil intermediate. This compound is then reacted with the appropriate aromatic amine to produce the desired compound of the invention.

Where one of R_1 and R_2 of the desired quinazolone is NH_2 , the appropriate quinazolone is prepared according to the previous paragraph, with an NO_2 group in the desired position, and the compound is then reacted with the appropriate reducing agent to reduce the NO_2 group to a NH_2 group.

- 6 -

Having the anticonvulsant substituted quinazolones compounds of the invention, a person skilled in the art can prepare N¹-oxide derivatives by reacting the compound with the appropriate oxidizing agent to oxidize the nitrogen in the 1-position.

DETAILED DESCRIPTION OF THE INVENTION

Reference will now be made in detail to the presently preferred embodiments of the invention, which, together with the following examples, serve to explain the principles of the invention.

The invention relates to anticonvulsant substituted quinazolones represented by Formula II and their physiologically acceptable acid addition salts. In one preferred embodiment of the invention, X₁ is nitrogen, sulfur, or oxygen. Preferably, X₁ is N or S, and most preferably it is N. When X₁ is N, S, or O, X₂ is CH.

In another preferred embodiment, one of R₁ and R₂ is NO₂ or NH₂. Preferably, one of R₁ and R₂ is NH₂, and the other is H.

In another preferred embodiment of the invention, R₃ and R₄ are alkyl containing 1-3 carbon atoms. Preferably, at least one of R₃ or R₄ is methyl. Most preferably, R₃ and R₄ are both methyl.

In another preferred embodiment of the invention, one or more of R₅, R₆, and R₇ are halogen.


- 7 -

In a particularly preferred embodiment, X_1 is N, X_2 is CH, and one of R_1 and R_2 is NO_2 or NH_2 . Preferably, one of R_1 and R_2 is NH_2 , and the other is H. In this case, it is also preferred that R_3 and R_4 are methyl and further that R_5 , R_6 , and R_7 are H.

In another particularly preferred embodiment of the invention, X_1 is N, X_2 is CH, and R_1 and R_2 are H. Most preferably, R_3 and R_4 are methyl and R_5 - R_7 are H, which provides the especially preferred compound 2-methyl-3-(3-methyl-2-pyridyl)-4-quinazolone.

In another particularly preferred embodiment of the invention, X_1 in Formula II is CH, X_2 is CH, and one of R_1 and R_2 is NO_2 or NH_2 . Most preferably, one of R_1 or R_2 is NH_2 and the other is H. In this case, R_3 and R_4 are preferably methyl, and R_5 , R_6 , and R_7 are H. Thus, another especially preferred compound of the invention is 2-methyl-3-o-tolyl-7-amino-4-quinazolone.

The compounds of the invention are prepared according to the following scheme:




This scheme is a modification of the scheme for synthesizing methaqualone, which is disclosed in references 1 and 2.

In particular, a substituted anthranilic acid represented by Formula III above is reacted with an anhydride represented by the Formula IV to prepare an anthranil precursor represented by Formula V. In these formulas, both R_1 and R_2 are H or one is NO_2 and the other is H. R_4 is alkyl with 1-5 carbon atoms. Preferably, the substituted anthranilic acid is refluxed in the presence of the anhydride under conditions readily determinable by persons skilled in the art, given the teachings contained therein.

The anthranil intermediate is then reacted with an aromatic amine represented by the following formula (and shown as RNH_2 above):

- 9 -




VI

This produces the substituted quinazolones of the invention, which are recovered by known techniques. Preferably, the recovered compounds are recrystallized one or more times to enhance their purity.

Where R_1 or R_2 in Formula II is NH_2 , a somewhat different synthesis is preferred. In particular, the desired substituted quinazolone is prepared according to the above scheme where one of R_1 and R_2 is NO_2 and the other is H. The NO_2 group is then reduced to NH_2 through the application of known reduction techniques and under reaction conditions that will be readily determinable to persons skilled in the art, given the teachings contained herein. Preferably, such reduction is accomplished by reacting the compound with a reducing agent, most preferably a mixture of iron and ammonium chloride.

It has been reported that methaqualone is metabolized in the body to the the N^1 -oxide of the compound (3). Accordingly, it is to be expected that the compounds of the inventions will be active in the mammalian body as N^1 -oxide derivatives of the compounds previously defined above. Thus, the invention also relates to N^1 -oxide derivatives of the compounds of the invention. Such compounds have the following formula:

- 10 -



VII

wherein X_1 , X_2 , and $R_1 - R_7$ are as previously defined.

Such compounds may be produced through the application of known techniques for oxidizing the nitrogen atom in compounds similar to the claimed compounds by a person skilled in the art without undue experimentation, once given the teachings contained herein. Preferably, the compounds of Formula II are refluxed with hydrogen peroxide under reaction conditions readily determinable by persons skilled in the art, given the teachings contained herein, for a sufficient time to produce the compounds of Formula VII.

The compounds of the invention (including the N¹-oxide derivatives) are useful for treating or preventing convulsions in mammals. The compounds or their acid addition pharmaceutically acceptable salts made be administered directly. Preferably, such compounds or salts are in admixture with a pharmaceutically acceptable carrier, providing a composition for treating or preventing convulsions in mammals.

- 11 -

The preferred animal host is any animal that may be subject to convulsions for which treatment or prevention is desired. These include, but are not limited to, humans and other primates, dogs, cats, cattle, swine, and horses. Preferably, the compounds and compositions are administered to humans.

The pharmaceutically acceptable acid addition salts of this invention can be prepared by standard methods known in the art, employing those acids of sufficient acidity to form acid addition salts with the N¹ or N¹-oxide oxygen of the compounds of this invention. These include salts derived from inorganic acids, such as hydrochloric acid, nitric acid, phosphoric acid, sulfuric acid, hydrobromic acid, hydriodic acid, phosphorous acid, and the like, as well as salts derived from organic acids, such as aliphatic mono- and di-carboxylic acids, phenyl-substituted alkanolic acids, hydroxy-alkanoic and -alkanedioic acids, aromatic acids, aliphatic, and aromatic sulfonic acids. Such pharmaceutically acceptable salts thus include the sulfate, metaphosphate, pyrophosphate, chloride, bromide, iodide, fluoride, oxalate, maleate, benzenesulfonate, toluenesulfonate, chlorobenzenesulfonate, methanesulfonate, propanesulfonate, naphthalene-1-sulfonate, naphthalene-2-sulfonate salts, and the like. The preferred salts are those derived from inorganic acids, especially hydrochloric acid.

The compounds of the invention may be administered as an anticonvulsant agent by various routes, including oral, parenteral rectal, transdermal, subcutaneous, intravenous, intramuscular, or intranasal routes. The preferred routes are oral and parenteral. They are usually employed in the

- 12 -

form of a pharmaceutical composition. The invention includes a pharmaceutical composition comprising from about 1% to about 95% by weight of the compounds, or a pharmaceutically acceptable acid addition salt thereof, associated with a pharmaceutically acceptable carrier.

In making the compositions of the present invention, the active ingredient will usually be mixed with a carrier, or diluted by a carrier, or enclosed within a carrier which may be in the form of a capsule, sachet, paper, or other container. When the carrier serves as a diluent, it may be a solid, semi-solid, or liquid material which acts as a vehicle, excipient, or medium for the active ingredient. Thus, the composition can be in the form of tablets, pills, powders, lozenges, sachets, cachets, elixirs, suspensions, emulsions, solutions, syrups, aerosols (as a solid or in a liquid medium), ointments containing, for example, up to 10% by weight of the active compounds, soft and hard gelatin capsules, suppositories, sterile injectable solutions, and sterile packaged powders.

Some examples of suitable carriers and diluents include lactose, dextrose, sucrose, sorbitol, mannitol, starches, gum acacia, calcium phosphate, alginates, tragacanth, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, methyl cellulose, methyl- and propyl-hydroxybenzoates, talc, magnesium stearate, and mineral oil. The formulations can additionally include lubricating agents, wetting agents, emulsifying and suspending agents, preserving agents, sweetening agents, flavoring agents, or other active ingredients. The compositions of the invention may be

- 13 -

formulated so as to provide quick, sustained, or delayed release of the active ingredient after administration to the patient.

The compositions will be preferably formulated in a unit dosage form, each dosage containing from about 50 to about 200 mg, preferably about 75 to about 150 mg, and most preferably about 80 to about 100 mg of the active ingredient. The term "unit dosage form" refers to physically discrete units suitable as unitary dosages for human subjects and other mammals, each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect, in association with the required pharmaceutical carrier.

The compounds are effective over a wide dosage range. For example, dosages per day will normally fall within the range of about 2 to about 8 mg/kg of body weight. In the treatment of adult humans, the range of about 1 to 2 mg/kg, in single or divided doses, is preferred. However, it will be understood that the amount of the compound actually administered will be determined by a physician or other person skilled in the art, in the light of the relevant circumstances, including the condition to be treated, the chosen route of administration, the age, weight, and response of the individual patient, the severity of the patient's symptoms, and the specific anticonvulsant substituted quinazolone or N¹-oxide derivative selected for use.

The chemical reactions described above are generally disclosed in terms of their broadest application to the preparation of the compounds of this invention.

- 14 -

Occasionally, the reactions may not be applicable as described to each compound included within the disclosed scope. The compounds for which this occurs will be readily recognized by those skilled in the art. In such cases, either the reactions can be successfully performed by conventional modifications known to those skilled in the art, e.g., by appropriate protection of interfering groups, by changing to alternative conventional reagents, by routine modification of reaction conditions, etc., or other reactions disclosed herein or otherwise conventional, will be applicable to the preparation of the corresponding compounds of this invention. In all the preparative methods, all starting materials are known or readily preparable from known starting materials.

It is to be understood that the application of the teachings of the present invention to a specific problem or environment will be within the capabilities of one having ordinary skill in the art in light of the teachings contained herein. Examples of the products of the present invention and processes for their preparation and use appear in the following examples.

EXAMPLE 1

Preparation of Acetantranils

Acetantranils were prepared by refluxing substituted anthranilic acids (0.27 mole) in acetic anhydride (200 ml) for 2 hours. Acetic anhydride was removed in vacuo, and the residues were recrystallized from benzene.

- 15 -

8-Azaacetanthranil was prepared by refluxing 2-aminonicotinic acid (0.1 mole) in acetic anhydride (50 ml) for 2 hours. Acetic anhydride was removed under reduced pressure, and the solid obtained was recrystallized from benzene.

Various anthranils synthesized are listed in Table 1.

EXAMPLE 2

Preparation of Substituted Quinazolones

Substituted quinazolones were prepared by heating equimolar proportions of appropriate primary amine and anthranil at a low flame. The jelly-like mass obtained on cooling was washed with ether. The solid separated out and was filtered and recrystallized from suitable solvents. All the quinazolones synthesized are listed in Table 2. Details about the synthesis of the most active compounds are found in Examples 3 and 4.

EXAMPLE 3

2-Methyl-3-(3-methyl-2-pyridyl)-4-quinazolone (compound no. 2)

Acetanthranil (4.5 g, 0.028 mole) was mixed with 2-amino-3-picoline (2.7 g, 0.025 mole) and the mixture was heated in an erlenmeyer flask, first at low heat and then at high heat over an open flame. The product was washed with ether and recrystallized from ethanol/water mixture. The yield was 3.7 g (58%), mp 135-137°C.

- 16 -

EXAMPLE 42-Methyl-3-o-tolyl-7-amino-4-quinazolone (compound no. 14)

This compound was prepared from 2-methyl-3-o-tolyl-7-nitro-4-quinazolone, which was prepared as follows. 7-nitro-acetantranil (2.1 g, 0.011 mole) was mixed with o-toluidine (1.1 g, 0.010 mole) and heated in an erlenmeyer flask, first over a low flame and then over a high flame to complete the reaction. On cooling overnight, the reaction mixture solidified. The solid mass was stirred and broken up after the addition of ether. Suction filtration yielded 2.7 g (98%), mp 183-186°C. After recrystallization from ethanol, the yield was 2.5 g (91%), mp 181-183°C.

To a mixture of 2.0 g of iron powder (reduced) and 1.0 g 2-methyl-3-o-tolyl-7-nitro-4-quinazolone (0.0036 mole) in a test tube (8" x 1") was added 2 ml of 1 N ammonium chloride and 8 ml ethanol. The mixture was warmed gently in a water bath until the initial vigorous reaction had subsided. The test tube was then heated in the water bath until the solvents had evaporated (about 1 hr). The residue was extracted with four 10 ml portions of benzene, and the extracts were suction-filtered. The filtrate was heated with stirring, and n-hexane was added to cloudiness. The suspension was placed in the refrigerator overnight, and the white crystals were removed by suction-filtration. The yield was 0.9 g (100%), mp 211-212°C.

- 17 -

EXAMPLE 52-Propyl-3-(2-methyl-4-chloro-phenyl)-4-guinazalone

This compound is prepared from butyranthranil, which is prepared as follows. Anthranilic acid (37.0 g, 0.270 mole) is refluxed with 200 ml butyric anhydride for two hours. The solvent is removed in vacuo (15 mm) with magnetic bar stirring, and the residue is dissolved in 100 ml benzene, filtered, and transferred to a beaker. The reaction flask is washed with 50 ml hot benzene. The washing is filtered and added to the benzene in the beaker. The benzene solution is concentrated to 100 ml by heating and allowed to cool to room temperature. The mixture is placed in the refrigerator overnight, then ground up in a mortar and pestle and suction-filtered. The crystals are air-dried and weighed.

Butyranthranil (5.3 g, 0.028 mole) is mixed with 2-methyl-4-chloro-aniline (3.6 g, 0.025 mole), and the mixture is heated in an erlenmeyer flask over an open flame, first at low heat and then at high heat to complete the reaction. The product is washed with ether and recrystallized from the appropriate solvent.

EXAMPLE 6Determination of anticonvulsant activity

Anticonvulsant activity was determined in male mice (Swiss-Webster, 20-25 g). The mice were divided in groups of 10, keeping the group weights equal as far as possible. The quinazolones shown in Table 2 as well as methaqualone

- 18 -

were injected ip (100 mg/kg) in a 5% aqueous suspension of gum acacia to one group of 10 animals. One hour after the administration of quinazolones, the mice were injected with pentylenetetrazol (90 mg/kg) sc under the loose skin of the back. This dose of pentylenetetrazol has been shown to produce convulsions in all untreated mice. The mice were then observed for the following 60 minutes for the occurrence of seizures. One episode of clonic spasm which persisted for a minimum period of 5 seconds was considered a threshold convulsion. Transient intermittent jerks or tremulousness were not taken into account. Animals devoid of even a threshold convulsion during the period of 60 minutes were considered protected. The number of animals protected in each group was recorded, and the anticonvulsant activity of these quinazolones was represented as percent protection. Mortality was recorded 24 hours after the pentylenetetrazol injection. After the injection of test compounds, behavioral observations were also made. Data are given in Table 3. The results show that compound no. 2 and compound no. 14 exhibited 100% protection against pentylenetetrazol seizures and that they did not exhibit any toxicity at the effective dosage.

EXAMPLE 7

Dose Response, Time Response, and Approximate LD₅₀

Dose response and time response studies were performed with compound no. 2 by injecting it into a group of 10 male Swiss-Webster mice. In addition, a group of 10 male ICR mice were injected with different dosages of compound no. 2 to determine the approximate LD₅₀. The

- 19 -

animals were observed for 24 hours, and the LD₅₀ was calculated. Results are given in Table 4.

In addition, compound no. 2 was also tested against Maximal Electric Shock (MES) seizure. Compound no. 2 exhibited 100% protection against MES at 30 mg/kg ip in mice.

EXAMPLE 8

Anticonvulsant Effect of Compound No. 2 in Rats

Compound No. 2 was also tested in rats. Four rats were treated with compound no. 2 at a dosage of 50 mg/kg orally. Anticonvulsant effects of compound no. 2 were observed at different time periods against both maximal electric shock seizures (MES) and pentylenetetrazol-induced seizure. The toxic symptoms were also observed. Data are given in Table 5. It can be seen from this table that compound no. 2 protected against both MES and pentylenetetrazol-induced seizure at all time periods without exhibiting any toxic symptoms.

Maximal electroshock seizures were elicited with a 60 cycle alternating current of 50mA intensity (5-7 times that necessary to elicit minimal electroshock seizures) delivered for 0.2 seconds via corneal electrodes. A drop of 0.9% saline was instilled in the eye prior to application of the electrodes in order to prevent the death of the animal. Abolition of the hind limb tonic extension component of the seizure was defined as protection.

- 20 -

As it appears from the results in Examples 6, 7, and 8, compounds 2 and 14 are effective anticonvulsants with higher therapeutic indices than methaqualone, indicating a wider safety margin.

- 21 -

TABLE 1Substituted Anthranils

R ₁	R ₂	X	m.p. °C	Recrystallization solvent
H	H	CH	78-80	Benzene
H	H	N	174-176	Benzene
NO ₂	H	CH	156-160	Benzene
H	NO ₂	CH	139-142	Benzene

- 22 -

TABLE 2Substituted Quinazolones*

Compound No.	R ₁	R ₂	R ₃	X ₁	X ₂	m.p. °C	Recrystallization solvent
2	H	H	CH ₃	N	CH	135-137	Ethanol-water
3	H	H	CH ₃	CH	N	148-150	Ethanol
4	H	H	CH ₃	N	N	252-253	Ethanol
5**	H	H	CH ₃	CH ₂	CH	160-162	Ethanol
6	H	H	COOH	CH	CH	244-246	Ethanol-water
7	H	H	NO ₂	CH	CH	155-165	Ethanol-water
8	H	H	NO ₂	N	CH	152-160	Ethanol
9	NO ₂	H	CH ₃	CH	CH	181-183	Ethanol
10	NH ₂	H	CH ₃	CH	CH	221-223	Benzene-n-hexane
11	NO ₂	H	CH ₃	N	CH	220-221	Ethanol
12	NH ₂	H	CH ₃	N	CH	250-253	Benzene-n-hexane
13	H	NO ₂	CH ₃	CH	CH	181-183	Ethanol
14	H	NH ₂	CH ₃	CH	CH	211-212	Benzene-n-hexane
15	H	NO ₂	CH ₃	N	CH	156-158	Ethanol
16	H	NH ₂	CH ₃	N	CH	201-203	Benzene-n-hexane

* All the compounds were characterized by sharp melting points and elemental analyses (C, H, & N within ±0.5%).

** In this compound, the ring at position 3 is saturated (cyclohexyl).

- 23 -

TABLE 3

Anticonvulsant Activity and gross CNS effects
of Substituted quinazolones

Compound No.	Percent Protection	24 Hour Mortality	Behavioral Observations
1 (Methaqualone)	100	0	deep hynosis
2	100	0	mild sedation
3	10	0	none
4	0	80	none
5	20	40	none
6	0	30	none
7	10	40	none
8	0	50	none
10	40	30	none
12	30	50	none
14	100	0	none
16	40	40	none

- 24 -

TABLE 4

Anticonvulsant effect of
2-methyl 3-(3-methyl-2-pyridyl)-4-quinazolone

Dose Response*

Dosage mg/kg, i.p.	Percent Protection against pentylenetetrazol (90mg/kg, s.c.) given 1 hour after the injection of the test compound.
40	20
60	80
80	90
100	100

* Group of 10 male mice (Swiss-Webster, 20-25g) were used for each time period. The test compound was given in 5% aqueous gum acacia suspension.

- 25 -

TABLE 4 (cont'd)Time Response**

Time after the injection of the test compound (hr)	Percent Protection against pentylentetrazol (90mg/kg s.c.)
1	100
2	60
3	0
4	0

Approximate LD₅₀

Approximate LD₅₀ was determined in male ICR mice.
Approximate LD₅₀ was found to be about 1000mg/kg, i.p.

** Group of 10 male mice (Swiss-Webster, 20-25g) were used for each time period. The test compound was given at a dosage of 100mg/kg, i.p. in 5% aqueous gum acacia suspension.

- 26 -

TABLE 5Anticonvulsant Effect of Compound No. 2*

Time after oral administration of Compound no. 2 (Hr.)	Percent protection against pentylenetetrazol	Percent protection against MES	Toxicity in percent rats
0.25	33.3**	75	0
0.5	75	50	0
1	25	75	0
2	0.1	50	0
4	25	25	0

* Group of four rats were used for each time period.
Compound no. 2 was given at a dosage of 50 mg/kg orally in
0.5% methylcellulose suspension.

** Three rats were used.

- 27 -


REFERENCES

1. Gujral, M.L., Saxena, P.N. and Tewari, R.S., Ind. J. Med. Res. 43, 637 (1955).
2. Gujral, M.L., Sareen, K.N., and Kohli, R.P., Ind. J. Med. Res. 45, 207 (1957).
3. Harvey, S.C. in Goodman and Gilman's The Pharmacological Basis of Therapeutics (eds. Gilman, Goodman, Ral, Murad), p. 365, seventh edition, Macmillan (1985).
4. Klosa, J. and Starke, H., Ger (East) patent 32,296 (Cl C 07d2), Nov. 25, 1964.
5. Kaupmann, W. and Funke, S., Ger patent 1,168,435 (Cl. Co7d) April 23, 1964.
6. Bianchi, C., and David, A., J. Pharm. Pharmacol. 12, 501 (1960).
7. Kretzschmar, E., Pharmazie, 35, 253 (1980).
8. Bhaduri, A.P. and Khanna, N.M., Ind. J. Chem. 4, 447 (1966).
9. Kohli, R.P., Gupta, T.K., Parmar, S.S., and Arara, R.C., Jap. J. Pharmacol. 17, 409 (1967).
10. Dwivedi, C. and Parmar, S.S., Curr. Sci. 41, 487 (1972).
11. Dwivedi, C., Misra, R.S., Chaudhari, A., and Parmar, S.S., J. Nat. Med. Assoc. 72, 953 (1980).

- 28 -

WE CLAIM:

1. An anticonvulsant compound represented by the formula:



wherein X_1 is N, S, O, or CH, X_2 is N or CH, R_1 and R_2 are H, NO_2 , or NH_2 except that when one of R_1 and R_2 is NO_2 or NH_2 the other is H, R_3 and R_4 are alkyl with 1-5 C atoms, and R_5 , R_6 , and R_7 are H or halogen, provided that when X_1 is N, S, or O, X_2 is CH, and pharmaceutically acceptable salts of said compound.

2. The compound or salt of Claim 1 wherein X_1 is N.
3. The compound or salt of Claim 1 wherein one of R_1 and R_2 is NO_2 or NH_2 .
4. The compound or salt of Claim 1 wherein R_3 and R_4 are methyl.
5. The compound or salt of Claim 1 wherein R_5 , R_6 , and R_7 are H.
6. The compound or salt of Claim 2 wherein one of R_1 and R_2 is NO_2 or NH_2 .

- 29 -

7. The compound or salt of Claim 2 wherein R_3 and R_4 are methyl.

8. The compound or salt of Claim 2 wherein R_5 , R_6 , and R_7 are H.

9. The compound or salt of Claim 2 wherein R_1 and R_2 are H.

10. The compound or salt of Claim 9 wherein R_3 and R_4 are methyl.

11. The compound of Claim 1 wherein said compound is 2-methyl-3-(3-methyl-2-pyridyl)-4-quinazolone.

12. The compound or salt of Claim 1 wherein X_1 is CH, X_2 is CH, and one of R_1 and R_2 is NO_2 or NH_2 .

13. The compound or salt of Claim 12 wherein R_3 and R_4 are methyl.

14. The compound or salt of Claim 13 wherein R_5 , R_6 , and R_7 are H.

15. The compound or salt of Claim 12 wherein one of R_1 and R_2 is NH_2 and the other is H.

16. The compound or salt of Claim 15 wherein R_3 and R_4 are methyl.

17. The compound or salt of claim 16 wherein R_5 , R_6 , and R_7 are H.

- 30 -

18. The compound of Claim 1 wherein said compound is 2-methyl-3-o-tolyl-7-amino-4-quinazolone.

19. A composition for treating or preventing convulsions in mammals comprising an amount of the compound or salt of Claim 1 effective for said treatment or prevention in a pharmaceutically acceptable carrier.

20. A method of treating or preventing convulsions in a mammal comprising administering a pharmaceutically effective amount of the compound or salt of Claim 1 to said mammal.

21. The method of Claim 20 wherein approximately 2 mg to 8 mg of said compound or salt is administered per kilogram of body weight of said mammal.

22. The method of Claim 21 wherein said compound or salt is administered orally or parenterally.


23. The method of Claim 22 wherein said mammal is a human.

24. A method of treating or preventing convulsions in a mammal comprising administering a pharmaceutically effective amount of the composition of Claim 19 to said mammal.


25. A method of making the compound of Claim 1 wherein both R_1 and R_2 are H or one of R_1 and R_2 is NO_2 and the other is H comprising the steps of:

- 31 -


reacting a substituted anthranilic acid represented by the formula:



wherein X_2 is N or CH and both R_1 and R_2 are H or one of R_1 and R_2 is NO_2 and the other is H with an anhydride represented by the formula $(R_4CO)_2O$ wherein R_4 is alkyl with 1-5 C atoms to produce an anthranil having the following formula:



and reacting said anthranil with an amine represented by the formula:




- 32 -


wherein X_1 is N, S, O, or CH, R_3 is alkyl with 1-5 C atoms, and R_5 , R_6 , and R_7 are H or halogen, to produce said compound.

26. A method of making the compound of Claim 1 wherein one of R_1 and R_2 is NH_2 and the other is H comprising the steps of:

reacting a substituted anthranilic acid represented by the formula:




wherein X_2 is N or CH and one of R_1 and R_2 is NO_2 and the other is H with an anhydride represented by the formula $(R_4CO)_2O$ wherein R_4 is alkyl with 1-5 C atoms to produce an anthranil having the following formula:




reacting said anthranil with an amine represented by the formula:

- 33 -




wherein X_1 is N, S, O, or CH, R_3 is alkyl with 1-5 C atoms, and R_5 , R_6 , and R_7 are H or halogen to produce a compound represented by the formula:



wherein one of R_1 and R_2 is NO_2 and the other is H; and


reacting said compound with a reducing agent to produce said compound of Claim 1 wherein one of R_1 and R_2 is NH_2 and the other is H.

27. An anthranil useful in the preparation of the compound of Claim 1 wherein said anthranil is represented by the formula:



wherein X_2 is N or CH, R_1 and R_2 are H or NO_2 , except that when one of R_1 and R_2 is NO_2 , the other is H, and R_4 is alkyl with 1-5 C.

28. An anticonvulsant compound comprising the N¹ oxide derivative of the compound of Claim 1 and represented by the formula:



wherein X_1 is N, S, O, or CH, X_2 is N or CH, R_1 and R_2 are H, NO_2 , or NH_2 except that when one of R_1 and R_2 is NO_2 or NH_2 the other is H, R_3 and R_4 are alkyl with 1-5 C atoms, and R_5 , R_6 , and R_7 are H or halogen, provided that when X_1 is N, S, or O, X_2 is CH, and pharmaceutically acceptable salts of said derivative compound.

INTERNATIONAL SEARCH REPORT

International Application No. PCT/US91/00783

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) ⁶ According to International Patent Classification (IPC) or to both National Classification and IPC IPC(5): A61K 31/505; C07D 471/00, 401/00, 239/72, 419/00; U.S.: 544/279, 284, 287, 290; 514/258, 259.																													
II. FIELDS SEARCHED <div style="text-align: center; margin-top: 10px;">Minimum Documentation Searched ⁷</div> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <th style="width: 25%;">Classification System</th> <th style="width: 75%;">Classification Symbols</th> </tr> <tr> <td style="padding: 5px;">U.S.</td> <td style="padding: 5px;">544/279, 284, 287, 290; 514/258, 259.</td> </tr> </table> <div style="text-align: center; margin-top: 10px;">Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched ⁸</div>			Classification System	Classification Symbols	U.S.	544/279, 284, 287, 290; 514/258, 259.																							
Classification System	Classification Symbols																												
U.S.	544/279, 284, 287, 290; 514/258, 259.																												
Chemical Abstracts (Computer Online)																													
III. DOCUMENTS CONSIDERED TO BE RELEVANT ⁹ <table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="width: 10%;">Category [*]</th> <th style="width: 60%;">Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²</th> <th style="width: 30%;">Relevant to Claim No. ¹³</th> </tr> </thead> <tbody> <tr> <td style="text-align: center;">Y</td> <td>US, A, 4,276,295 (ISHIKAWA) 30 June 1981, (Note: Col. 7, lines 20-65).</td> <td style="text-align: center;">1-19, 25-27</td> </tr> <tr> <td style="text-align: center;">Y</td> <td>US, A, 3,304,304 (Claassen) 14 February 1967, (Note Col. 1, lines 1-65).</td> <td style="text-align: center;">25-27</td> </tr> <tr> <td style="text-align: center;">Y</td> <td>US, A, 3,748,325 (SOMASEKHARA) 24 July, 1973, (Note Figures 1-5).</td> <td style="text-align: center;">25-27</td> </tr> <tr> <td style="text-align: center;">X</td> <td>US, A, 3,162,634 (KLOSA) 22 December 1964, (Note Table 1, No.'s 4-7).</td> <td style="text-align: center;">1-19 25-27</td> </tr> <tr> <td style="text-align: center;">X,Y</td> <td>US, A, 3,414,573 (BREUER) 03 December 1968, (Note col. 1-4).</td> <td style="text-align: center;">1-27</td> </tr> <tr> <td style="text-align: center;">X,Y</td> <td>GB, A, 997,652 (EPROVA LTD.) 07 July 1965, (Note: page 3, lines 10-35; page 2 lines 1-70).</td> <td style="text-align: center;">1-27</td> </tr> <tr> <td style="text-align: center;">X,Y</td> <td>FR, M, 139,728 (SUMITOMO CHEMICAL CO.) 13 February 1968 (Note Col's 1-3).</td> <td style="text-align: center;">1-27</td> </tr> <tr> <td style="text-align: center;">Y</td> <td>US, A, 3,755,581 (JANIAK) 28 August 1973, (Note: Col. 2, Col. 5, lines 1-45).</td> <td style="text-align: center;">1-27</td> </tr> </tbody> </table>			Category [*]	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³	Y	US, A, 4,276,295 (ISHIKAWA) 30 June 1981, (Note: Col. 7, lines 20-65).	1-19, 25-27	Y	US, A, 3,304,304 (Claassen) 14 February 1967, (Note Col. 1, lines 1-65).	25-27	Y	US, A, 3,748,325 (SOMASEKHARA) 24 July, 1973, (Note Figures 1-5).	25-27	X	US, A, 3,162,634 (KLOSA) 22 December 1964, (Note Table 1, No.'s 4-7).	1-19 25-27	X,Y	US, A, 3,414,573 (BREUER) 03 December 1968, (Note col. 1-4).	1-27	X,Y	GB, A, 997,652 (EPROVA LTD.) 07 July 1965, (Note: page 3, lines 10-35; page 2 lines 1-70).	1-27	X,Y	FR, M, 139,728 (SUMITOMO CHEMICAL CO.) 13 February 1968 (Note Col's 1-3).	1-27	Y	US, A, 3,755,581 (JANIAK) 28 August 1973, (Note: Col. 2, Col. 5, lines 1-45).	1-27
Category [*]	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³																											
Y	US, A, 4,276,295 (ISHIKAWA) 30 June 1981, (Note: Col. 7, lines 20-65).	1-19, 25-27																											
Y	US, A, 3,304,304 (Claassen) 14 February 1967, (Note Col. 1, lines 1-65).	25-27																											
Y	US, A, 3,748,325 (SOMASEKHARA) 24 July, 1973, (Note Figures 1-5).	25-27																											
X	US, A, 3,162,634 (KLOSA) 22 December 1964, (Note Table 1, No.'s 4-7).	1-19 25-27																											
X,Y	US, A, 3,414,573 (BREUER) 03 December 1968, (Note col. 1-4).	1-27																											
X,Y	GB, A, 997,652 (EPROVA LTD.) 07 July 1965, (Note: page 3, lines 10-35; page 2 lines 1-70).	1-27																											
X,Y	FR, M, 139,728 (SUMITOMO CHEMICAL CO.) 13 February 1968 (Note Col's 1-3).	1-27																											
Y	US, A, 3,755,581 (JANIAK) 28 August 1973, (Note: Col. 2, Col. 5, lines 1-45).	1-27																											
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p>[*] Special categories of cited documents: ¹⁰</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&" document member of the same patent family</p> </div> </div>																													
IV. CERTIFICATION <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%; padding: 5px;"> Date of the Actual Completion of the International Search <div style="text-align: center;">23 JUNE 1991</div> </td> <td style="width: 50%; padding: 5px;"> Date of Mailing of this International Search Report <div style="text-align: center;">17 JUL 1991</div> </td> </tr> <tr> <td style="width: 50%; padding: 5px;"> International Searching Authority <div style="text-align: center;">ISA/US</div> </td> <td style="width: 50%; padding: 5px;"> Signature of Authorized Officer <div style="text-align: center;">MATTHEW V. GRUMBLING</div> </td> </tr> </table>			Date of the Actual Completion of the International Search <div style="text-align: center;">23 JUNE 1991</div>	Date of Mailing of this International Search Report <div style="text-align: center;">17 JUL 1991</div>	International Searching Authority <div style="text-align: center;">ISA/US</div>	Signature of Authorized Officer <div style="text-align: center;">MATTHEW V. GRUMBLING</div>																							
Date of the Actual Completion of the International Search <div style="text-align: center;">23 JUNE 1991</div>	Date of Mailing of this International Search Report <div style="text-align: center;">17 JUL 1991</div>																												
International Searching Authority <div style="text-align: center;">ISA/US</div>	Signature of Authorized Officer <div style="text-align: center;">MATTHEW V. GRUMBLING</div>																												